List of Excipients in Branded Drug PLEGRIDY

Plegridy Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Plegridy, Biogen’s peginterferon beta-1a, uses a compact excipient system designed to stabilize a PEGylated protein in a low-volume subcutaneous injection. The commercial opportunity is concentrated in four areas: high-quality injectable excipients, ready-to-use formulation components, prefilled delivery systems, and biosimilar manufacturing support. Plegridy’s principal formulation barriers are protein aggregation, surface adsorption, oxidation, particulate control, container compatibility, and cold-chain stability.

What is Plegridy and how is it formulated?

Plegridy is a recombinant interferon beta-1a molecule covalently linked to a 20-kDa polyethylene glycol group. Biogen markets it for adults with relapsing forms of multiple sclerosis. The product is administered subcutaneously every 14 days after dose titration [1].

The United States formulation contains:

Component	Function
Peginterferon beta-1a	Active pharmaceutical ingredient
Sodium acetate trihydrate	Buffering agent
Acetic acid	pH adjustment
Polysorbate 20	Surfactant and anti-adsorption excipient
Water for injection	Vehicle

The formulation has an acidic pH of approximately 4.5. Commercial presentations include prefilled syringes and single-dose prefilled pens. The principal maintenance strength is 125 micrograms in 0.5 mL; lower strengths support titration during treatment initiation [1].

The excipient list is short, but the formulation is technically demanding. Biologic products can lose potency or develop aggregates from agitation, temperature excursions, air-liquid interfaces, contact with silicone oil, or interaction with container surfaces. PEGylation can improve pharmacokinetics while creating its own analytical and stability requirements.

What excipients protect Plegridy stability?

Polysorbate 20

Polysorbate 20 reduces adsorption of peginterferon beta-1a to glass, elastomer, and device surfaces. It also limits interfacial stress during filling, shipping, and injection.

The commercial risk is polysorbate degradation. Hydrolysis and oxidation can generate degradation products, including free fatty acids and peroxides. Those species can promote protein oxidation, subvisible particles, and changes in product appearance. A biosimilar developer would need to control:

• Polysorbate concentration and lot variability
• Peroxide burden
• Hydrolytic degradation during shelf life
• Interaction with silicone oil and elastomer components
• Impact of agitation and freeze-thaw exposure

Polysorbate 20 is widely available, so the opportunity is not basic supply alone. Higher-value suppliers can compete through low-peroxide grades, tighter fatty-acid profiles, pharmaceutical-grade documentation, and data packages supporting protein compatibility.

Acetate buffer

Sodium acetate trihydrate and acetic acid establish the acidic environment used for the drug product. Acetate buffers are commercially familiar and relatively inexpensive. Their strategic value lies in consistency and control rather than exclusivity.

Potential supplier differentiation includes:

• Low bioburden and endotoxin control
• Low trace-metal content
• Consistent molar concentration
• Strong elemental-impurity documentation
• Reliable supply for sterile manufacturing
• Compatibility with low-volume fill-finish processes

A formulation developer would not normally gain durable differentiation from acetate alone. The commercial value comes from the complete formulation and its validated manufacturing process.

Water for injection

Water for injection is a standard injectable vehicle. It is not a meaningful product-level barrier, but it remains critical to batch consistency, endotoxin compliance, and aseptic processing.

PEGylated interferon compatibility

The dominant formulation challenge is the active molecule, not the commodity excipients. PEGylated interferon beta-1a requires control of:

• High-molecular-weight aggregates
• Deamidation and oxidation
• PEG cleavage or altered PEG distribution
• Potency and receptor-binding activity
• Subvisible and visible particles
• Adsorption to primary packaging
• Concentration-dependent viscosity and injectability

The formulation must preserve biological activity while remaining compatible with a 0.5-mL injection and an automated delivery device.

What commercial opportunities exist in Plegridy excipients?

The most attractive opportunities are in specialized injectable excipient supply and formulation services rather than in generic acetate or water-for-injection sales.

Low-peroxide polysorbate supply

A supplier that can provide polysorbate 20 with controlled peroxide values, defined degradation profiles, and strong lot-to-lot consistency can target Plegridy-like biologics and biosimilar programs. The same capability applies to monoclonal antibodies, fusion proteins, vaccines, and other subcutaneous biologics.

The commercial proposition includes:

1. Pharmaceutical-grade polysorbate 20.
2. Analytical methods for peroxide and free-fatty-acid monitoring.
3. Stability data in protein formulations.
4. Dual sourcing and supply continuity.
5. Regulatory support for global filings.

Excipient premixes and formulation kits

A ready-to-use acetate/polysorbate system could reduce development time for biosimilar developers. Such products would need defined composition, sterilization compatibility, and regulatory documentation. The opportunity is stronger for contract development and manufacturing organizations than for a standalone commodity excipient vendor.

Primary packaging and device compatibility

Plegridy is supplied in prefilled delivery systems. This creates opportunities in:

• Low-silicone or controlled-silicone syringes
• Cyclic olefin polymer containers
• Elastomeric plunger components
• Low-extractables needle shields
• Autoinjector-compatible cartridges
• Device systems that reduce shaking and residual volume

A packaging platform that reduces protein adsorption or particulate formation can produce a stronger commercial position than a conventional excipient substitution.

Analytical and stability services

Contract laboratories can support Plegridy-like products through:

• Size-exclusion chromatography
• Capillary electrophoresis
• Peptide mapping
• PEG distribution analysis
• Potency assays
• Subvisible particle testing
• Polysorbate degradation testing
• Container-closure interaction studies
• Shipping and agitation simulation

These services are relevant to both biosimilar development and lifecycle management.

What patents protect Plegridy and its formulation?

Plegridy is a biologic, so its protection is distributed across biologic exclusivity, composition claims, PEGylation technology, manufacturing processes, formulations, delivery devices, and method-of-use claims. It does not receive the same Orange Book patent-listing treatment as a conventional small-molecule drug.

Public product information identifies peginterferon beta-1a as the active substance but does not, by itself, establish the complete current patent estate. Patent families may cover:

• PEGylated interferon beta molecules
• Site-specific or controlled PEG conjugation
• Purification and characterization
• Stable liquid formulations
• Subcutaneous administration
• Dose regimens
• Prefilled syringes and injection devices
• Methods for treating relapsing multiple sclerosis

A current FTO review would need to examine U.S., European, Canadian, Japanese, and other national-stage records, including continuations, divisionals, terminal disclaimers, patent-term adjustments, and maintenance status. Patent expiry cannot be inferred reliably from the FDA label or the product’s approval date.

Is Plegridy listed in the Orange Book?

Plegridy is a biologic product, not a conventional small-molecule drug. The Orange Book is therefore not the primary patent reference for Plegridy. Biologic reference-product information is evaluated through the FDA’s Purple Book and the Biologics Price Competition and Innovation Act framework [2, 3].

This distinction affects generic-entry analysis. A conventional ANDA and Paragraph IV strategy is generally not the normal route for a biosimilar version of Plegridy.

When does Plegridy lose regulatory exclusivity?

The FDA approved Plegridy on August 15, 2014 [4]. Under the BPCIA, a reference biologic generally receives 12 years of reference-product exclusivity from first licensure, subject to statutory rules and possible pediatric exclusivity. On that basis, the principal U.S. biologic exclusivity period associated with Plegridy would extend into 2026, with the precise date dependent on FDA determinations concerning first licensure and any applicable pediatric extension [2].

Regulatory exclusivity does not eliminate patent risk. A biosimilar applicant may face patents that expire after biologic exclusivity ends. Conversely, the end of biologic exclusivity does not guarantee immediate market entry.

What is the Paragraph IV equivalent for Plegridy?

The BPCIA does not use the Hatch-Waxman Paragraph IV mechanism for biologics in the same way as the ANDA pathway. A biosimilar applicant submits a 351(k) application and may participate in the statutory patent-information exchange and litigation process commonly called the “patent dance” [2].

A Plegridy biosimilar could therefore encounter:

• Patent-listing and notice disputes
• Declaratory-judgment actions
• Infringement litigation
• Preliminary injunction requests
• Manufacturing-process claims
• Device and formulation claims
• Settlement agreements controlling launch timing

The litigation profile would depend on the patent families asserted at the time of filing.

What biosimilar risks exist for Plegridy?

Plegridy faces a moderate long-term biosimilar risk. The active protein is less complex than many monoclonal antibodies, but biosimilar development still requires extensive analytical and clinical comparability work.

Key development barriers include:

• Demonstrating comparable PEGylation characteristics
• Matching interferon beta-1a biological activity
• Establishing comparable immunogenicity
• Controlling aggregates and particles
• Reproducing the low-volume subcutaneous presentation
• Validating device performance
• Establishing interchangeability, where sought
• Managing manufacturing scale and cold-chain logistics

The product’s every-two-week dosing schedule and established multiple-sclerosis indication support commercial demand. The opportunity is strongest for a developer that can offer a lower-cost product with a differentiated autoinjector, reliable supply, or broader regional access.

How do formulation patents affect generic or biosimilar launch timing?

Formulation patents can delay entry even when composition-of-matter or biologic exclusivity has ended. Claims directed to acetate concentration, surfactant use, pH, protein concentration, or container compatibility can create litigation risk if drafted broadly enough to cover a biosimilar formulation.

A developer can reduce exposure through:

• A non-infringing buffer system
• An alternative surfactant
• Different polysorbate concentration
• A lyophilized presentation
• A different container material
• A distinct device configuration
• A manufacturing process that avoids asserted claims

Formulation changes carry comparability and regulatory costs. A technically non-infringing formulation may require additional stability, immunogenicity, device, or usability work.

Which companies are positioned to compete with Plegridy?

Competition comes from three groups.

Branded multiple-sclerosis products

Plegridy competes with other disease-modifying therapies, including interferon beta products, glatiramer acetate, oral agents, monoclonal antibodies, and high-efficacy therapies. Its every-two-week administration offers a convenience advantage over older interferon regimens, but oral and infusion products compete on adherence, efficacy perceptions, and patient preference.

Biosimilar developers

Potential entrants include companies with established recombinant-protein manufacturing, PEGylation capabilities, and injectable-device infrastructure. The most credible developers are likely to have:

• Existing interferon or biosimilar experience
• Analytical platforms for PEGylated proteins
• Sterile fill-finish capacity
• Regional regulatory expertise
• Commercial access to neurology channels

Excipient and CDMO suppliers

Suppliers such as major pharmaceutical excipient manufacturers and biologics CDMOs can participate without marketing a competing drug. Their products may include low-peroxide polysorbate, acetate buffer systems, sterile formulation services, device assembly, and stability testing.

What FDA regulatory issues affect Plegridy excipient commercialization?

An excipient change in a marketed biologic can require comparability data and, depending on the change, a supplement or other regulatory submission. The regulatory burden depends on whether the change affects critical quality attributes, manufacturing controls, product performance, or stability.

For a Plegridy-like product, regulators would focus on:

• Protein identity and purity
• Potency
• Aggregation
• Particles
• Degradation products
• Sterility and endotoxin
• Extractables and leachables
• Container-closure integrity
• Device dose delivery
• Stability under intended storage conditions

Novel excipients face greater regulatory friction than established parenteral excipients. A supplier with a history of injectable use and robust toxicology documentation has a commercial advantage.

How strong is the Plegridy excipient strategy?

Plegridy’s formulation strategy is commercially efficient rather than compositionally complex. It uses established excipients in a liquid, ready-to-inject system. That simplifies manufacturing and patient use but limits formulation-based differentiation.

The stronger barriers are:

1. PEGylated active-substance manufacture.
2. Analytical comparability.
3. Protein stability in a prefilled device.
4. Regulatory history and clinical data.
5. Patent claims covering the molecule, process, formulation, or device.

The excipient system alone is unlikely to block competition. It can, however, raise development costs when combined with tight specifications, container compatibility requirements, and device-performance expectations.

What revenue exposure does Plegridy face from biosimilar entry?

Plegridy revenue is exposed to three commercial pressures:

• Price erosion after biosimilar approval
• Formulary substitution or contracting
• Migration to newer high-efficacy multiple-sclerosis therapies

Biosimilar entry would not necessarily eliminate branded demand. Biogen could retain patients through contracting, patient-support programs, device familiarity, supply reliability, and physician confidence. A biosimilar with an equivalent prefilled pen and lower net price would create greater substitution pressure than a product requiring a new administration method.

Key Takeaways

• Plegridy uses peginterferon beta-1a in an acetate-buffered liquid formulation with polysorbate 20 and water for injection.
• Polysorbate 20 quality, peroxide control, and container compatibility are the main excipient opportunities.
• Commodity acetate and water provide limited differentiation; integrated formulation and device services offer greater value.
• Plegridy is governed primarily by biologic exclusivity and BPCIA procedures, not the conventional Orange Book Paragraph IV pathway.
• The FDA approved Plegridy in August 2014, placing the principal 12-year reference-product exclusivity period in 2026, subject to statutory determinations and any pediatric extension.
• Biosimilar barriers center on PEGylation comparability, protein stability, immunogenicity, device performance, and patent scope.
• Formulation and device patents may affect launch timing after biologic exclusivity ends.
• The strongest commercial opportunities are low-peroxide polysorbate, injectable formulation development, prefilled-device compatibility, analytical testing, and biosimilar manufacturing support.

FAQs

Can polysorbate 20 be replaced in a Plegridy biosimilar?

Potentially, but substitution would require development and comparability evidence covering protein stability, aggregation, potency, particles, immunogenicity risk, and container compatibility. A replacement surfactant could also create new regulatory and patent issues.

Does Plegridy require refrigerated storage?

Yes. Plegridy is stored under refrigerated conditions and must be protected from light. Temperature excursions and shipping stress are important formulation and packaging considerations [1].

Is a Plegridy biosimilar the same as a generic interferon?

No. A biosimilar is developed under the FDA’s 351(k) biologics pathway and must demonstrate high similarity to the reference biologic. It is not approved through the standard small-molecule ANDA process.

Are Plegridy’s excipients likely to be patent-protected independently?

The individual excipients are established pharmaceutical materials and generally offer limited standalone exclusivity. Patent risk is more likely to arise from a specific combination, concentration range, pH, manufacturing process, container system, or device configuration.

What is the most valuable commercial position in the Plegridy supply chain?

A validated low-peroxide polysorbate system combined with biologic formulation, analytical, and prefilled-device support has greater strategic value than supplying acetate buffer or water for injection alone.

References

1. Biogen. (2024). Plegridy (peginterferon beta-1a) injection: U.S. prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2023). Questions and answers on biosimilar development and the BPCI Act. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/questions-and-answers-biosimilar-development-and-bpci-act

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Food and Drug Administration. (2014, August 15). FDA approves new treatment for multiple sclerosis. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-multiple-sclerosis